Laramée, Philippe
Brodtkorb, Thor-Henrik
Rahhali, Nora
Knight, Chris
Barbosa, Carolina
François, Clément
Toumi, Mondher
Daeppen, Jean-Bernard
Rehm, Jürgen
Clinical trials referenced in this document:
Documents that mention this clinical trial
The cost-effectiveness and public health benefit of nalmefene added to psychosocial support for the reduction of alcohol consumption in alcohol-dependent patients with high/very high drinking risk levels: a Markov model
https://doi.org/10.1136/bmjopen-2014-005376
Documents that mention this clinical trial
The cost-effectiveness and public health benefit of nalmefene added to psychosocial support for the reduction of alcohol consumption in alcohol-dependent patients with high/very high drinking risk levels: a Markov model
https://doi.org/10.1136/bmjopen-2014-005376
Documents that mention this clinical trial
The cost-effectiveness and public health benefit of nalmefene added to psychosocial support for the reduction of alcohol consumption in alcohol-dependent patients with high/very high drinking risk levels: a Markov model
https://doi.org/10.1136/bmjopen-2014-005376
Documents that mention this clinical trial
The cost-effectiveness and public health benefit of nalmefene added to psychosocial support for the reduction of alcohol consumption in alcohol-dependent patients with high/very high drinking risk levels: a Markov model
https://doi.org/10.1136/bmjopen-2014-005376
Documents that mention this clinical trial
The cost-effectiveness and public health benefit of nalmefene added to psychosocial support for the reduction of alcohol consumption in alcohol-dependent patients with high/very high drinking risk levels: a Markov model
https://doi.org/10.1136/bmjopen-2014-005376
Documents that mention this clinical trial
The cost-effectiveness and public health benefit of nalmefene added to psychosocial support for the reduction of alcohol consumption in alcohol-dependent patients with high/very high drinking risk levels: a Markov model
https://doi.org/10.1136/bmjopen-2014-005376
Documents that mention this clinical trial
The cost-effectiveness and public health benefit of nalmefene added to psychosocial support for the reduction of alcohol consumption in alcohol-dependent patients with high/very high drinking risk levels: a Markov model
https://doi.org/10.1136/bmjopen-2014-005376
Documents that mention this clinical trial
The cost-effectiveness and public health benefit of nalmefene added to psychosocial support for the reduction of alcohol consumption in alcohol-dependent patients with high/very high drinking risk levels: a Markov model
https://doi.org/10.1136/bmjopen-2014-005376
Documents that mention this clinical trial
The cost-effectiveness and public health benefit of nalmefene added to psychosocial support for the reduction of alcohol consumption in alcohol-dependent patients with high/very high drinking risk levels: a Markov model
https://doi.org/10.1136/bmjopen-2014-005376